Therapeutic Apheresis Market

Therapeutic Apheresis Market Outlook

The demand for therapeutic apheresis is estimated to rise at a CAGR of 6.8% during the forecast period. The global therapeutic apheresis market share is projected to be valued at USD 2,717.9 million in 2023 and is expected to reach USD 5,264.4 million by 2033.

The demand for therapeutic apheresis is surging owing to growing incidences of chronic diseases and an increasing number of trauma and injury cases.

Apheresis is a procedure wherein blood is withdrawn from a donor’s body, extraction of one or more blood components such as platelets, plasma, and white blood cells, and transfusing of the remaining blood back into the donor during the procedure or at the end of it. Therapeutic apheresis is a process of removing blood components from a patient with apheresis technology.

Therapeutic apheresis is used for removing defective cells. It is also used for the treatment of conditions in which a component or a pathogenic substance in the blood causes morbidity.

Basically, there are three types of therapeutic apheresis procedures used, namely therapeutic plasma exchange (TPE), red blood cell exchange (RBCX), and cellular depletion. Therapeutic plasma exchange is the elimination of a huge volume of plasma from the patient and replacing the plasma with suitable fluids. TPE is commonly used for the treatment of autoimmune diseases or immune-mediated diseases or disorders.

TPE removes paraproteins, monoclonal antibiotics, antigen-antibody, and autoimmune antibody complexes. Therapeutic apheresis particularly removes the significant proportion of one or more components causing diseases.

What Is Driving The Global Therapeutic Apheresis Sector?

• Growing need for several blood components, increasing prevalence of accidents globally, and additional government initiatives toward blood donation are a few primary drivers accelerating the therapeutic apheresis industry.
• The growing dominance of various therapeutic procedures such as fluid replacement therapy, red cell exchange, dendritic cells cancer therapy, car T cells therapy, and extracorporeal therapy is broadly stirring the growth rate of the global market.
• Escalating trauma and injury cases, growing cases of chronic diseases, rising need for blood components and more awareness pertaining to blood safety, favorable reimbursement policies, and a growing number of complicated surgical procedures are all responsible for the lucrative growth of the market.
• Constantly increasing geriatric population coupled with increasing healthcare expenditure and growing use of therapeutic apheresis in treating cancer is likely to boost the growth of the global therapeutic apheresis sector.

Attributes	Value
Therapeutic Apheresis Market Size (2023)	USD 2,717.9 million
Therapeutic Apheresis Market Projected Size (2033)	USD 5,264.4 million
Therapeutic Apheresis Market CAGR (2023 to 2033)	6.8%

Restraining Factors Hampering The Market Growth

• Therapeutic apheresis procedures, apheresis devices, and installing the apheresis devices are an expensive affair and therefore the high cost associated with these procedures is anticipated to obstruct the growth of the therapeutic apheresis business.
• Lack of awareness coupled with a dearth of qualified specialists and problems associated with apheresis methods is likely to suppress the global market expansion.
• Apheresis results in the growing occurrence of several disorders and diseases such as the growth of germ cell tumors from stem cells of the germ line and early embryo, Guillain-Barré syndrome, Paraproteinemia, Waldenstrom's macroglobulinemia, non-Hodgkin’s lymphoma, symptomatic myeloma, and many others are broadly hindering the growth of the market.

Rental model’s installation of apheresis devices, strict donor recruitment criteria, and decreased blood donations using apheresis as a result of lack of awareness are likely to restrict the market further over the forecast period.

Regional Analysis

Countries	Market Share (2022)
United States	28.8%
Germany	6.3%
Japan	4.2%

North America To Dominate The Therapeutic Apheresis Industry

North America accounted for the leading share, i.e. 32.6% market share in 2022. Factors like growing demand for plasma-derived medicines production and well-established healthcare infrastructure. This region has smooth accessibility to advanced blood collection technologies. It also has the presence of some of the significant apheresis companies in the region.

Additionally, reasons such as soaring initiatives by the government towards blood donation coupled with the rising need for blood components across the globe. Moreover, approval of the latest indications for apheresis treatment, such as acute disseminated encephalomyelitis, autoimmune haemolytic anemia, and neonatal cardiac lupus, support the growth of the market in this region.

Europe Likely To Portray A Promising Market For Therapeutic Apheresis

In 2022, Europe accounted for 29.8% market share in the global market, owing to the growing prevalence of blood disorders such as profuse bleeding and a decrease in platelet count.

This region witnessed increasing cases of chronic diseases such as autoimmune diseases and cancer, and a growing number of organ donors also is supporting the growth of the market in this region.

The escalation in the rate of occurrence of chronic diseases, growing necessity for plasma sources, additional activities considering blood safety, and an increasing number of complicated surgical procedures are also fuelling the Europe therapeutic apheresis sector.

Start-up Ecosystem In The Therapeutic Apheresis Industry

In June 2022, BioCaptiva raised nearly USD 2.6 million in the latest seed funding to additionally develop its BioCaptis instrument which is an apheresis-based cell-free DNA capture device for using liquid biopsy testing. The financial round was led by existing investor Archangels, who joined Scottish Enterprise, Cancer Research Horizons, and novel investor Old College Capital.

Key Players Benchmarking The Therapeutic Apheresis Industry

The market has an oligopolistic structure and is characterized by frequent mergers and acquisitions. Industry companies frequently employ new product development and strategic partnerships as sustainability strategies.

• Terumo BCT (US) and UniCAR-Therapy Bio-Medicine Technologies Co. cooperated in October 2019. (China). By establishing a new Shanghai Center of Excellence, this alliance aims to advance CAR T-cell therapy. This advancement also enabled Terumo to expand the scope of its apheresis and leukapheresis applications.
• Fresenius Kabi invested EUR 30 million in the Dominican Republic to construct an apheresis and transfusion disposables facility in January 2020.

Key Players

• Asahi Kasei Medical Co.
• Haemonetics Corporation
• Miltenyi Biotec
• Cerus Corporation
• Terumo BCT Inc.
• Fresenius Kabi USA
• Terumo Bct
• B. Braun Melsungen AG
• Nikkiso Co. Ltd.
• Medica S.p.A.
• Baxter Healthcare Corporation
• Kawasumi Laboratories Inc.
• Therakos Incorporation

Key Segments

By Procedure Types:

• Therapeutic Plasma Exchange (TPE)
• Red Blood Cell Exchange (RBCX)
• Cellular Depletions

By Technology:

• Centrifugation
• Membrane filtration

By Application:

• Hematology
• Neurology
• Nephrology
• Rheumatology
• Oncology
• Others

By End User:

• Hospitals
• Blood banks
• Specialty clinics

By Region:

• North America
• Latin America
• Asia Pacific
• MEA
• Europe

Frequently Asked Questions

What is the Therapeutic Apheresis Market CAGR for 2033?

The Therapeutic Apheresis Market CAGR for 2033 is 5.2%.

How Big Will the Therapeutic Apheresis Market be by 2033?

The market is estimated to reach USD 5,264.4 million by 2033.

Who are the Key Therapeutic Apheresis Market Players?

Key market players in the Therapeutic Apheresis Market are Terumo BCT, Inc., Fresenius SE & Co. KGaA, and Haemonetics Corporation.

What is the Current Market Valuation of the Therapeutic Apheresis Market?

The market is estimated to secure a valuation of USD 2,717.9 million in 2023.

What are the Current Trends in the Therapeutic Apheresis Market?

The market for apheresis is being driven by an increase in chronic disorders. Personal apheresis is expanding with new technology and home use. Patient security is a top priority.